Related by context. All words. (Click for frequent words.) 71 PXD# 68 obatoclax 68 HuLuc# 67 elotuzumab 67 OXi# 67 GRN#L 66 aflibercept 66 ganetespib 66 vascular disrupting agent 66 neratinib 66 HGS ETR1 66 Sym# 66 Symadex 66 INCB# [001] 66 CA4P 65 Dacogen injection 65 AEG# 65 PS# [001] 65 oxidative stress inducer 65 imetelstat 65 atacicept 65 ocrelizumab 65 dacetuzumab 65 tesmilifene 65 cilengitide 65 pertuzumab 65 Virulizin ® 64 PEG SN# 64 BRAF inhibitor 64 XmAb# 64 HGS# 64 axitinib 64 HuMax EGFr 64 phase IIb clinical 64 HGS ETR2 64 Amigal 64 alvespimycin 64 daclizumab 64 Hsp# inhibitor 64 sapacitabine 63 PRT# 63 enzastaurin 63 CBLC# 63 MGd 63 angiogenesis inhibitor 63 AP# [003] 63 ISIS # 63 figitumumab 63 HQK 63 HuMax CD# 63 INGN 63 NXL# 63 BZL# 63 MGCD# [001] 63 Azedra 63 HCD# [002] 63 ProLindac 63 rNAPc2 63 voreloxin 63 PLX# 63 forodesine 63 vandetanib 63 MDV# 63 phase IIb trial 63 HuMax CD4 62 Virulizin R 62 TACI Ig 62 Asentar 62 JAK inhibitor 62 indibulin 62 CYT# 62 cediranib 62 glufosfamide 62 eniluracil 62 antitumor 62 ASA# 62 Phase Ib clinical 62 seliciclib 62 motesanib 62 MAXY G# 62 TRO# 62 palifosfamide 62 Panzem R NCD 62 RGB # 62 BAY #-# 62 Tyrima 62 IMA# 62 Xanafide 62 pomalidomide 62 Exherin TM 62 sunitinib malate 62 pralatrexate 62 tanespimycin 62 YONDELIS 62 ridaforolimus 62 talabostat 62 Canvaxin 62 Tarvacin TM 62 Cloretazine R VNP#M 62 Imprime PGG 62 Hsp# inhibition 62 JAK inhibitors 62 Actilon 62 EndoTAG TM -1 62 corticosteroid dexamethasone 62 Ocrelizumab 62 EGFr 62 phase IIa clinical 62 decitabine 62 Aplidin 62 PEG Interferon lambda 62 molecularly targeted 62 tremelimumab 62 CR# vcMMAE 62 tivozanib 62 XL# [003] 62 AQ4N 62 otelixizumab 62 immunomodulatory 62 PCK# 62 ELACYT 62 cMET 62 vidofludimus 62 RLY# 61 PSMA ADC 61 MEK inhibitors 61 Bicifadine 61 anti leukemic 61 Telcyta 61 MEK inhibitor RDEA# 61 UVIDEM 61 VEGF Trap 61 Aurora kinase 61 Zerenex 61 deforolimus 61 bardoxolone 61 perifosine 61 Tarvacin 61 Cloretazine 61 eprotirome 61 nucleoside 61 Panzem 61 IMC A# 61 SNT MC# 61 Atiprimod 61 TELCYTA 61 riociguat 61 IRX 2 61 CEQ# 61 entinostat 61 antiangiogenic 61 brivaracetam 61 TREANDA 61 sunitinib 61 evaluating tivozanib 61 phenoxodiol 61 #D#C# 61 celgosivir 61 torezolid phosphate 61 FOLOTYN ® 61 Ceflatonin 61 anticancer agent 61 PSN# [002] 61 ataluren 61 ponatinib 61 Amrubicin 61 farletuzumab 61 pan HDAC inhibitor 61 clofarabine 61 preclinically 61 belinostat 61 OHR/AVR# 61 Eribulin 61 phase IIb 61 tyrosine kinase inhibitor 61 alkylating agent 61 HDAC inhibitors 61 Gleevec resistant 61 zanolimumab 60 elacytarabine 60 PLK1 SNALP 60 velafermin belinostat 60 lintuzumab 60 picoplatin 60 triphendiol 60 CCX# 60 ENMD # 60 Onconase 60 ularitide 60 tubulin inhibitor 60 Targretin 60 Azixa 60 Debio 60 registrational trial 60 Alpharadin 60 valopicitabine 60 Nanobody 60 adecatumumab 60 ongoing Phase 1b 60 hematological cancers 60 omacetaxine 60 JAK3 60 ASONEP 60 vicriviroc 60 Akt activation 60 ToGA 60 MEK inhibitor 60 oral prodrug 60 hedgehog pathway 60 mapatumumab 60 OncoVEX GM CSF 60 mTOR inhibition 60 LAF# 60 selective androgen receptor modulator 60 vascular disrupting agents 60 c MET 60 Cethrin 60 MLN# 60 RG# [001] 60 targeting CD# 60 lumiliximab 60 JAK2 60 nitazoxanide 60 anticancer activity 60 Phase Ib II 60 antibody MAb 60 ANA# 60 Tavocept 60 depsipeptide 60 T DM1 60 Neuradiab 60 docetaxel chemotherapy 60 darapladib 60 varespladib 60 IAP inhibitor 60 lapatinib Tykerb 60 SRT# [003] 60 DXL# 60 Vandetanib 60 ofatumumab 60 SERMs 60 anticancer therapies 60 LUX Lung 60 vosaroxin 60 Vidaza azacitidine 60 kinase inhibitor 60 Reolysin 60 bortezomib 60 IFN α 60 Phase Ib 60 Aviptadil 60 CYT# potent vascular disrupting 60 Elesclomol 60 HDAC inhibition 60 proteasome inhibitor 60 Squalamine 60 IgG1 antibody 60 LY# [003] 60 investigational humanized monoclonal antibody 60 Thiovir 60 VEGF receptor 60 epigenetic therapies 60 velafermin 60 Phase #b/#a 60 MAGE A3 ASCI 60 ON #.Na 60 TRV# [001] 60 Genasense 59 Blinatumomab 59 EGF receptor 59 Stimuvax 59 EGFR inhibitors 59 ACZ# 59 Azedra TM 59 proteasome inhibitors 59 HCV protease 59 epothilone 59 afatinib 59 regorafenib 59 lorvotuzumab mertansine 59 R#/MEM # 59 apoptotic pathway 59 vismodegib 59 selective inhibition 59 OvaRex R 59 topotecan 59 relapsed ovarian cancer 59 CTLA 4 59 teduglutide 59 Proxinium TM 59 compound PMX # 59 antitumor effects 59 SYMMETRY trial 59 ELND# 59 YONDELIS R 59 Exelixis XL# 59 Epratuzumab 59 DACH platinum 59 metaglidasen 59 menadione 59 Cotara 59 protein kinase inhibitor 59 blinatumomab 59 trodusquemine 59 Temsirolimus 59 thrombopoietin 59 CoFactor 59 oral antiviral 59 IL #E 59 ZK EPO 59 Plicera 59 Curaxin 59 OvaRex ® MAb 59 LymphoStat B 59 anti angiogenic 59 teriflunomide 59 milatuzumab 59 Dasatinib 59 anticancer agents 59 phase Ib 59 Troxatyl 59 pazopanib 59 Archexin 59 Perifosine 59 IMP# 59 PEP# [003] 59 APOPTONE 59 GSK # 59 BNC# 59 PI3K inhibitor 59 MYDICAR ® 59 dirucotide 59 panitumumab Vectibix 59 ENMD 59 Panitumumab 59 Dapagliflozin 59 Omacetaxine 59 Phase 2a trial 59 angiogenesis inhibition 59 Theratope 59 chemopreventive agent 59 iniparib 59 iSONEP 59 TNFerade 59 CRD5 59 Tasimelteon 59 brostallicin 59 Elotuzumab 59 cancer immunotherapies 59 midstage studies 59 Icatibant 59 PI3K/mTOR 59 Mipomersen 59 liposomal formulation 59 volociximab 59 deacetylase inhibitors 59 uric acid lowering 59 fosbretabulin 59 Sphingomab 59 ATL/TV# 59 lupus nephritis 59 favorable pharmacokinetic profile 59 MERLIN TIMI 59 VEGFR2 59 B Raf 59 nab paclitaxel 59 C1 INH 59 Laquinimod 59 phosphate S1P 59 TPI ASM8 59 rFVIIIFc 59 telomerase therapeutic 58 RANK ligand 58 TRAIL induced apoptosis 58 T#I [002] 58 laquinimod 58 PDE4 inhibitor 58 PARP inhibitors 58 ZYBRESTAT 58 anticancer therapy 58 rindopepimut 58 standard chemotherapy regimen 58 Annamycin 58 Talabostat 58 teplizumab 58 relapsed multiple myeloma 58 ONCONASE 58 oral Azacitidine 58 preclinical studies 58 HSP# inhibitor 58 BCIRG 58 Phase Ib study 58 Hematide 58 OncoVEX 58 TRISENOX 58 Bortezomib 58 #ME# 58 FOLOTYN 58 bevacizumab Avastin ® 58 apricitabine 58 custirsen 58 HER2 positive metastatic breast 58 SUTENT 58 therapeutic monoclonal antibody 58 rhIL 7 58 Carfilzomib 58 amrubicin 58 Insegia 58 seliciclib CYC# 58 StemEx R 58 TBC# 58 ALN RSV# 58 SUCCEED trial 58 EpCAM 58 Seliciclib 58 WT1 58 synthetic retinoid 58 GMX# 58 flavopiridol 58 Traficet EN 58 drug conjugate 58 ATL# [001] 58 oral mTOR inhibitor 58 vorinostat 58 erlotinib Tarceva 58 chemoresistance 58 GED aPC 58 incyclinide 58 TOCOSOL Paclitaxel 58 RDEA# 58 oral FTY# 58 GAP #B# 58 Pertuzumab 58 Nanobody ® 58 VNP#M 58 Atrasentan 58 LHRH antagonists 58 Zybrestat 58 BIBW 58 Betaferon ® 58 MetMAb 58 bortezomib Velcade 58 Allovectin 7 58 HER2 antibody 58 Vectibix 58 Tanespimycin 58 aleglitazar 58 Alzhemed TM 58 HCV protease inhibitor 58 recurrent glioblastoma multiforme 58 viral kinetics 58 Ceflatonin R 58 miR #a [002] 58 multicenter Phase II 58 Alocrest 58 subcutaneous formulation 58 GSK3 58 Nexavar sorafenib 58 CCR2 58 hematologic malignancies 58 eculizumab 58 samalizumab 58 oral JAK1 58 midstage trials 58 Fodosine 58 proteasome inhibitor bortezomib 58 Hsp# inhibitors 58 epothilones 58 OPAXIO 58 JAK1 58 humanized monoclonal antibody 58 Catena ® 58 tasimelteon 58 IMC #B 58 Defibrotide 58 CCR9 antagonist 58 Phase 1b 58 anticancer compound 58 thymidylate synthase TS 58 Trastuzumab 58 AMPK activators 58 Alemtuzumab 58 TroVax 58 GSK# [002] 58 docetaxel Taxotere R 58 glucagon receptor 58 IMGN# 58 solithromycin 58 Anacetrapib 58 TTF Therapy 58 methylnaltrexone 58 investigational monoclonal antibody 58 huC# DM4 58 Litx 58 bavituximab 58 ONCONASE R 58 squalamine 58 nonclinical studies 58 antitumor activity 58 EGFR tyrosine kinase inhibitors 58 senicapoc 58 CENP E 58 radiation sensitizer 58 ancrod 58 gamma secretase inhibitor 58 MOZOBIL 58 viral kinetic 58 orally bioavailable 58 L BLP# 58 Cloretazine ® 58 Cetrorelix 58 Factor VIIa 58 nucleoside analog 58 FTY# 58 fostamatinib 58 ImmunoVEX HSV2 58 IAP inhibitors 58 cannabinor 58 Zolinza 58 GRNVAC1 58 Viramidine 58 anti EGFR antibody 58 Muraglitazar 58 Desmoteplase 58 pradefovir 58 Golimumab 58 #beta HSD1 58 ApoB SNALP 58 EVIZON 57 CRLX# 57 nucleotide analog 57 cytostatic 57 canakinumab 57 metastatic renal cell carcinoma 57 bone metastasis 57 oncolytic virus 57 gemcitabine cisplatin 57 DFMO 57 AMD# [003] 57 myeloproliferative disorders 57 Phase Ib clinical trials 57 bendamustine 57 Phase 1b trial 57 ADI PEG 57 mTOR inhibitors 57 ixabepilone 57 REP# 57 Allovectin 7 R 57 tafamidis 57 cetuximab Erbitux 57 BRIM2 57 MNTX 57 chemokine receptor 57 GVAX 57 TELINTRA 57 zalutumumab 57 resolvins 57 PF # [001] 57 Tarceva TM 57 atrasentan 57 ALN VSP 57 Xelox 57 INCB# [002] 57 BiTE 57 Cloretazine R 57 subcutaneous PRO 57 Hedgehog signaling pathway 57 CD# antibody [001] 57 CUDC 57 IGF 1R 57 satraplatin 57 bevacizumab Avastin 57 HDACi 57 Wnt signaling pathway 57 LEP ETU 57 PARP inhibitor 57 Amplimexon 57 MyVax R 57 Abiraterone acetate 57 Bezielle 57 CLORETAZINE TM VNP#M 57 Vitaxin 57 HRPC 57 trastuzumab Herceptin R 57 EGFR HER2 57 antibody MT# 57 talactoferrin 57 NVA# 57 Velcade bortezomib 57 isavuconazole 57 dexpramipexole 57 cytokine refractory 57 telaprevir VX 57 Amphinex ® 57 panobinostat 57 novel anticancer 57 GW# [003] 57 XL# SAR# 57 nimotuzumab 57 DermaVir Patch 57 Phase 2b trial 57 Glufosfamide 57 GGF2 57 REOLYSIN ® 57 Vernakalant 57 Darusentan 57 romidepsin 57 OMP #M# 57 GFT# 57 CCR5 mAb 57 Gefitinib 57 Prestara 57 Santhera 57 ALS #-# 57 CIMZIA TM 57 TH# [003] 57 Phase III clinical 57 Apaziquone 57 SUTENT ® 57 immunomodulator 57 Talactoferrin 57 MAXY alpha 57 DAVANAT 57 Telintra 57 pro apoptotic 57 isoform selective 57 mertansine 57 NV1FGF 57 veltuzumab 57 Antisense 57 PEGylated interferon beta 1a 57 renin inhibitors 57 Tarceva erlotinib 57 sorafenib 57 Phase IIa trials 57 OZURDEX ® 57 BiTE antibody 57 trastuzumab DM1 T DM1 57 refractory AML 57 PD LID 57 IDX# 57 Vidofludimus 57 antitumor effect 57 pharmacological chaperone 57 temozolomide 57 anti CD3 antibody 57 sorafenib Nexavar 57 pediatric acute lymphoblastic 57 R roscovitine 57 AeroLEF TM 57 Tß4 57 QLT# 57 TRAIL receptor antibodies 57 azacitidine 57 midstage clinical 57 rFIXFc 57 Phase III psoriasis 57 tipranavir 57 novel VDA molecule 57 HDAC Inhibitor 57 Randomized Phase 57 histone deacetylase HDAC inhibitor 57 Stimuvax R 57 Hepatocellular Carcinoma HCC 57 Voreloxin 57 fenretinide 57 Xinlay 57 trabectedin 57 Lu AA# 57 BAL# [002] 57 tecarfarin 57 GRN# 57 Viprinex 57 NEUMUNE 57 KNS # 57 Trizytek 57 crizotinib PF # 57 elvucitabine 57 JAK2 inhibitor 57 epigenetic therapeutics 57 TOLAMBA 57 alfimeprase 57 SGLT2 57 gefitinib Iressa 57 virus HCV protease inhibitor 57 LY# [002] 57 CLL8 57 dasatinib 57 Neulasta ® 57 Quinamed 57 CaPre TM 57 trastuzumab emtansine T DM1 57 SinuNase 57 chemotherapeutic regimen 57 trabedersen 57 Erlotinib 57 HCV protease inhibitors 57 immune modulating 57 antiangiogenic therapy 57 erlotinib Tarceva ® 57 DOS# 57 FLT3 57 Hsp# Inhibitor 57 ThGRF 57 Vidaza 57 sodium glucose cotransporter 57 HGS ETR1 mapatumumab 57 Hedgehog antagonist 57 mipomersen 57 refractory gout 57 VEGF inhibitors 57 ACE2 57 Epothilones 57 MBP# [001] 57 vinca alkaloid 57 induces apoptosis 57 Varespladib 57 EndoTAGTM 1 57 bone metastases 57 Phenoptin 57 HER2 positive breast cancer 57 nucleoside analogue 57 AKT inhibitor 57 mitogen activated ERK kinase 57 Synavive 57 Panzem R 57 c MYC 57 HDAC inhibitor 57 induce apoptosis 57 lomitapide 57 Cloretazine VNP#M 57 tranilast 57 Romidepsin 57 ostarine 57 VAPRISOL 57 nalbuphine ER 57 cleavable linker 57 Fludara 57 noninfectious uveitis 57 PROSTVAC TM 57 Resten NG 57 VIDAZA 57 Phase 2a 57 personalized immunotherapy 57 IL# PE#QQR 56 Myelodysplastic syndromes MDS 56 Phase 1b clinical 56 intratumoral injection 56 fibrotic disease 56 Phase IIIb clinical 56 abiraterone 56 BioNumerik 56 antiproliferative effects 56 paclitaxel Taxol 56 NU# [001] 56 GGTase 56 CCR9 56 RNAi therapeutic targeting 56 SAR# [004] 56 tipifarnib 56 Preclinical studies suggest 56 Virulizin 56 CD#L 56 Corlux 56 integrase inhibitor 56 STAT3 56 trastuzumab DM1 56 ProSavin 56 CDP# 56 XYOTAX TM 56 myelofibrosis polycythemia vera 56 preclinical 56 TLR9 agonists 56 confirmatory Phase III 56 DepoVax 56 registrational 56 PTP 1B 56 TG# [003] 56 Dacogen decitabine 56 A3 adenosine receptor 56 TLE3 56 TKM ApoB 56 daptomycin 56 Maribavir 56 platinum refractory 56 TLK# 56 Taxotere ® 56 PRTX 56 HspE7 56 Lenocta 56 Phase IIa clinical 56 CGEN # 56 relapsing remitting multiple sclerosis 56 investigational compound 56 ganaxolone 56 Fulvestrant 56 Lorianne Masuoka MD 56 UPLYSO 56 antiviral compounds 56 gastrin 56 ERK signaling 56 BCX# 56 dalbavancin 56 ADVEXIN 56 PI3K 56 sorafenib Nexavar ® 56 pharmacodynamic 56 Nexavar 56 Nanobodies ® 56 receptor tyrosine kinase inhibitor 56 pafuramidine 56 sodium thiosulfate STS 56 Aplidin R 56 CDK inhibitor 56 adecatumumab MT# 56 EOquin 56 PEGPH# 56 TroVax ® 56 TYZEKA 56 immune modulator 56 Valortim R 56 siRNA therapeutics 56 rBChE 56 antiangiogenic agents 56 QVA# 56 delta isoform 56 cytotoxic 56 Allovectin 7 ® 56 pharmacodynamic PD 56 galiximab 56 Diamyd ® 56 palifermin 56 vascular disrupting 56 Sapacitabine 56 Panzem NCD 56 heavily pretreated 56 registrational studies 56 Ostarine 56 Deforolimus 56 VitiGam 56 anti angiogenesis 56 ISTODAX 56 Angiolix 56 anti amnesic 56 Omacetaxine mepesuccinate 56 brentuximab vedotin 56 tesetaxel 56 carfilzomib 56 ARIKACE ™ 56 MT#/MEDI-# 56 non nucleoside HCV 56 nonsmall cell lung cancer 56 Fibrillex TM 56 P#X# 56 thymalfasin 56 BRIM3 56 sphingosine 1 56 VA# [002] 56 CTGF 56 ANG# 56 pharmacokinetic interactions 56 BiTE antibodies 56 Interferon alpha 56 enoximone 56 Nexavar ® 56 Vilazodone 56 lenalidomide dexamethasone 56 BAL# [001] 56 Shigamabs ® 56 Folotyn 56 Fc fusion protein 56 CTCE 56 omecamtiv mecarbil 56 HCV replication 56 p# inhibitors 56 ThermoDox R 56 Phase #/#a 56 Phase IIb trials 56 TMC# [002] 56 BCR ABL 56 SOD1 56 Aflibercept 56 glatiramer acetate 56 peroxisome proliferator activated 56 afamelanotide 56 multikinase inhibitor 56 Trofex TM 56 kinase inhibition 56 preclinical models 56 retinoid 56 Sudhir Agrawal D.Phil 56 Personalized Immunotherapy 56 RSD# oral 56 PKCi 56 Hedgehog pathway 56 selective modulator 56 ARRY 56 Beta catenin pathway 56 Exelixis compounds 56 EGFR TKI 56 Enzastaurin 56 ThermoDox ® clinical 56 demethylating agents 56 GeneICE 56 radezolid 56 ALTU 56 Nuvion 56 anti fibrotic 56 phase IIa 56 immunomodulation 56 pegfilgrastim 56 compound AEZS 56 S/GSK# 56 delafloxacin 56 posaconazole 56 sorafenib tablets 56 investigational hepatitis C 56 Irinotecan 56 CytoFabTM 56 Ramoplanin 56 Chemokine 56 Aurora Kinase 56 pegylated liposomal doxorubicin 56 cobiprostone 56 sargramostim 56 vemurafenib 56 APTIVUS 56 Campath ® 56 mTOR kinase 56 Opexa 56 LentiVector technology 56 LymphoStat B TM 56 FTIs 56 tolerability profiles 56 inhibitor RG# 56 leukotriene pathway 56 Pimavanserin 56 cytoprotective 56 pharmacodynamic effects 56 rHuPH# 56 idarubicin 56 pain palliation 56 clusterin 56 opioid induced bowel dysfunction 56 OMAPRO 56 AAG geldanamycin analog 56 NFκB 56 apremilast 56 Copegus ribavirin 56 immune modulatory 56 vernakalant oral 56 protein tyrosine phosphatase 1B 56 CD# CEA 56 interferon gamma 1b 56 investigational therapies 56 boosted protease inhibitor 56 faropenem 56 vaso occlusive crisis 56 Ixempra 56 immunomodulatory effects 56 PI3K delta 56 phase 2a 56 anti proliferative 56 PROMACTA 56 danoprevir 56 DP b# 56 insulin sensitizer 56 Teplizumab 56 AEGR 56 HDAC 56 Fx #A 56 standard chemotherapy regimens 56 preclinical efficacy 56 antisense 56 pharmacokinetic PK 56 TNF α 56 EOquin TM 56 Erbitux cetuximab 56 tezampanel 56 GM CSF 56 PARP inhibition 56 pro angiogenic 56 antiviral efficacy 56 CYC# 56 MYDICAR 56 glucokinase activator 56 Raptiva R 56 bortezomib Velcade ® 56 Stat5 56 small molecule defensin 56 factor receptor FGFR 56 Onco TCS 56 Tezampanel 56 MGCD# [002] 56 Revlimid lenalidomide 56 Pazopanib 56 ZACTIMA 56 gefitinib 56 Pralatrexate